Why MRI is the starting point — and where it falls short

An MRI scan is typically the first structured look inside a symptomatic knee — non-invasive, no radiation, and capable of showing cartilage, menisci, ligaments, and subchondral bone in a single appointment. For focal cartilage defects specifically, standard sequences can reveal where tissue loss has occurred and give an initial impression of depth and extent. Clinicians sometimes supplement routine sequences with T2 mapping or dGEMRIC, both of which provide compositional data on cartilage quality beyond what standard morphological imaging captures. At the Lincolnshire Knee Regeneration Hub in Sleaford, AI-assisted onMRI™ analysis can add automated cartilage segmentation and T2 mapping to the reporting process.

The important caveat is that MRI consistently underestimates how large a defect actually is. A peer-reviewed study by Gomoll (PMC4297136; n=38 knees) found that the true post-debridement defect area was, on average, 65% larger than the MRI estimate. Eighty-five per cent of individual defects exceeded their MRI-predicted size, with the degree of discrepancy ranging from 47% to 377% depending on lesion location.

Treatment pathways are partly size-driven, so a defect that looks small on a scan may cross a clinically relevant threshold once assessed in full. MRI is reliable for confirming that a focal defect exists and for guiding the initial referral decision — it is not the definitive measurement on which final treatment planning rests. That assessment belongs to a specialist consultation.

How cartilage defects are graded and sized

Cartilage thickness loss in the knee is described using two overlapping grading systems — ICRS (International Cartilage Repair Society) and Outerbridge — both running from 0 to 4. Grade 0 is normal cartilage; grades I and II represent partial-thickness softening or wear affecting less than half the cartilage depth. Grades III and IV are the clinically significant range: grade III means deep wear beyond the halfway point, and grade IV means the cartilage is gone entirely, leaving subchondral bone exposed. These are the grades that a regenerative intervention such as ChondroFiller is designed to address.

The second key variable is the area of the defect, measured in cm². The clinical literature uses three broad bands: under 2 cm², which may suit marrow-stimulation techniques; 2–4 cm², where several approaches overlap; and above 4 cm², where structural reconstruction options come into play. ChondroFiller targets focal, contained defects — published evidence covers lesions up to 6 cm² depending on delivery route, though the current outpatient ultrasound-guided injection pathway is best suited to focal contained lesions. Exact suitability should be confirmed at a specialist consultation.

Neither grading criterion applies to diffuse cartilage loss. Widespread joint-surface degeneration consistent with advanced osteoarthritis sits outside the ChondroFiller indication — the device is designed for a focal problem with defined boundaries, not generalised wear.

Who is a candidate for ChondroFiller injection

For most patients considering ChondroFiller, three broad eligibility factors apply: the defect is focal and contained within a defined area of the knee surface; it falls within the symptomatic ICRS or Outerbridge grade III–IV range; and conservative management — physiotherapy, activity modification, and standard analgesics — has not provided adequate relief. The outpatient ultrasound-guided injection pathway accommodates focal defects up to 6 cm², making it applicable across a wider size range than some earlier cartilage techniques.

Several factors point away from the injection pathway. Significant joint malalignment that has not been assessed or planned for correction is one: if load distribution across the knee surface is poor, a cartilage scaffold placed into a mechanically loaded defect is unlikely to perform well. Uncontained lesions — where the defect edge extends to the cartilage border rather than being surrounded by intact tissue — are also poorly suited, because the in-situ gelling mechanism depends on a defined cavity to hold the scaffold in place.

One practical implication for anyone reviewing their own scan: because MRI underestimates true defect area by an average of 65% (Gomoll, PMC4297136; n=38 knees), a lesion that appears just within the injection-pathway range may prove larger at specialist assessment. Candidacy is confirmed in clinical context, not assumed from a report figure alone.

For patients with larger or more structurally complex defects, MACI is a well-evidenced surgical alternative — but it involves a meaningfully different pathway: first, a cell-harvest biopsy taken under arthroscopy; then, weeks later, a separate surgical implantation procedure. ChondroFiller's injection pathway is single-stage, with no interim cell harvest. Which route is appropriate for a given knee depends on defect profile, overall joint condition, and clinical history — a specialist assessment is the right place to settle that question.

What happens during the ChondroFiller outpatient appointment

Arriving at the clinic, patients do not need to fast, arrange a general anaesthetic, or plan an overnight stay. The ChondroFiller product itself — a CE-marked Class III acellular collagen hydrogel manufactured by Meidrix Biomedicals GmbH in Germany — is delivered as a straightforward outpatient injection, typically completed within a single appointment.

Once the skin over the knee has been prepared, the treating clinician uses real-time ultrasound to guide the needle to the defect site. This image guidance allows precise placement rather than estimation by landmarks alone. The product arrives as two liquid components that are combined immediately before injection; once inside the joint, the liquid undergoes rapid in-situ polymerisation, gelling within minutes into a three-dimensional type I collagen scaffold that sits flush with the surrounding cartilage surface. No incisions, no sutures, no theatre admission.

The scaffold then acts as a structural and chemotactic environment — supporting the body's own repair processes through acellular matrix-induced chondrogenesis. Progenitor cells from the synovium and subchondral bone migrate into the matrix over the following months, gradually producing repair tissue. This is not an overnight process: the biological response continues for up to 6–24 months after the injection.

Technique precision at the time of injection is clinically meaningful. A 2025 prospective study (Demmer et al., PMC12498443) confirmed that flush application — filling the defect exactly to the level of surrounding cartilage — supports appropriate repair, whereas overfilling was associated with fibrous tissue formation. Patients typically leave on the same day, with crutches available for the first few days if needed.

Recovery timeline and published outcomes

The repair process unfolds over months rather than days. Crutches are typically needed only for the first two or three days; light weight-bearing is usual within one to three weeks, and most patients reach full functional recovery between three and six months. The biological response — progenitor cells migrating into the scaffold and producing repair tissue — continues for up to 24 months, so early milestones do not reflect the full picture.

Published knee data provides three headline anchors. International Knee Documentation Committee (IKDC) scores improve by an average of approximately 30 points at 12 months, a clinically meaningful shift. MOCART scores — the MRI-based measure of scaffold integration — have been reported in the 70–87 range, indicating solid radiological incorporation of the collagen matrix. In cohort data, around 80% of patients described their results as good or very good and said they would undergo the procedure again; symptom relief rates of 70–85% are cited across published series.

The most direct comparative evidence comes from Demmer et al. (PMC12498443, 2025), a prospective study using arthroscopic follow-up to assess cartilage quality directly. Treated patients showed a median Outerbridge score of 1.5 versus 3.0 in controls (P=0.006) and a median ICRS grade of 1 versus 3 (P=0.002) — a statistically significant difference in tissue quality.

Data beyond two years is still accumulating, and randomised head-to-head comparisons with surgical cartilage techniques remain limited. The evidence that exists supports meaningful short-to-medium-term benefit; longer-term durability is the open question.

Accessing ChondroFiller in the UK and booking an assessment

ChondroFiller is CE-marked for use in the UK but does not hold FDA approval in the United States. In the UK it is self-funded: it is not currently available on the NHS and is not covered by major private medical insurers including Bupa and AXA. Published guide cost ranges in the clinical literature run from approximately £3,000 to £8,000 per session, inclusive of consultation, ultrasound guidance, the product itself, and follow-up; current pricing should be confirmed with the treating clinic at the time of assessment.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral, with no NHS-style waiting lists. Assessment clinics are available at Sleaford NG34 — the group's head office, which houses an Open MRI suite and Regeneration Hub — and at Grantham NG31 for consultation and diagnostics.

If your MRI has identified a focal grade III–IV cartilage defect and conservative management has not provided adequate relief, a specialist assessment is the logical next step: it is the point at which imaging findings, clinical history, and candidacy criteria come together to determine whether the injection pathway is appropriate for your knee. Book an assessment at lincolnshireknee.co.uk.